Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma

Jung, Yong Wook; Kim, Sang Wun; Kim, Sung Hoon; Kim, Jae Hoon; Cho, Nam Hoon; Kim, Jae Wook; Kim, Young Tae

doi:10.1016/j.ejogrb.2009.09.011

Cited by 10 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Celecoxib or SC-560 treatment alone demonstrated a significantly prolonged mean survival time and MST in comparison with the control group in vivo. Recent clinical studies have provided convincing evidence of poor survival in patients who demonstrated high COX-2 expression in stage IIB cervical adenocarcinoma and breast cancer (16,17). Erkinheimo et al (18) suggested that elevated expression of COX-2 is associated with reduced survival in serous ovarian carcinomas.…”

Section: Discussionmentioning

confidence: 99%

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Zhang

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study was designed to investigate whether cyclooxygenase (COX) inhibitors (coxibs) could prolong survival time by attenuating the tumor growth of ovarian cancer xenograft-bearing mice. Tumor growth and survival time were observed and compared in mice which were treated with a COX-1 inhibitor (SC-560) and a COX-2 inhibitor (celecoxib) every other day for a 21 day period from the day of tumor formation. The trial lasted a total of 121 days. The combination therapy resulted in statistically significant inhibition of tumor size compared with the control group (P<0.05). Additionally, single treatment of SC-560 or celecoxib significantly prolonged the mean survival time of mice compared with the control group (P<0.05). We suggest that COX-1 and COX-2 inhibitors may improve survival and inhibit tumor growth, and that the tumor growth inhibition by coxibs may be the contributing factor for the prolonged survival time in mouse xenograft models.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Zhang

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Over expression of COX-2 has been considered an indicator of metastatic invasiveness in different malignancies including cervical carcinoma [41]. However, COX-2 is a strong predictor of poor response to radiotherapy or chemoradiation, irrespective of the histologic type [40,42].…”

Section: Carcinoma Embryonic Antigen (Cea)mentioning

confidence: 99%

Cervical cancer: Biomarkers for diagnosis and treatment

Dasari

Rajendra

Valluru

2015

Clinica Chimica Acta

163

138

View full text Add to dashboard Cite

“…14 In vitro studies demonstrate overexpression of COX-1 and COX-2 in cervical carcinogenesis. 15 The mechanisms of action of aspirin and acetaminophen in cervical oncogenesis proposed by other studies include inhibition of inflammation and angiogenesis related to COX-1 and COX-2, 12,16 induction of apoptosis, 10,17 and reduction of estradiol, 18 which has been shown to stimulate HPV oncogene expression 19 and cervical carcinogenesis. 20 …”

mentioning

confidence: 98%

Aspirin and Acetaminophen Use and the Risk of Cervical Cancer

Friel

Liu

Kolomeyevskaya

et al. 2015

Journal of Lower Genital Tract Disease

View full text Add to dashboard Cite

Objective In this study, we investigated whether regular use of aspirin or acetaminophen was associated with risk of cervical cancer in women treated at an American cancer hospital. Methods This case-control study included 328 patients with cervical cancer and 1,312 controls matched on age and decade enrolled. Controls were women suspected of having but not ultimately diagnosed with a neoplasm. Analgesic use was defined as regular (at least once per week for ≥6 months), frequent (≥7 tablets/week), very long term (≥11 years), or frequent, long term (≥7 tablets per week for ≥5 years). Results Compared to nonusers, frequent aspirin use was associated with decreased odds of cervical cancer (odds ratio, 0.53; 95%confidence interval, 0.29–0.97). A slightly larger association was observed with frequent, long-term use of aspirin (odds ratio, 0.46; 95% confidence interval, 0.22–0.95). Acetaminophen use was not associated with the risk of cervical cancer. Conclusions Our findings suggest that frequent and frequent, long-term use of aspirin is associated with decreased odds of cervical cancer. To our knowledge, this is the first US-based study examining these associations. Given the widespread use of nonsteroidal anti-inflammatory drugs and acetaminophen worldwide, further investigations of the possible role of analgesics in cervical cancer, using a larger sample size with better-defined dosing regimens, are warranted.

show abstract

Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma

Cited by 10 publications

References 19 publications

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Cervical cancer: Biomarkers for diagnosis and treatment

Aspirin and Acetaminophen Use and the Risk of Cervical Cancer

Contact Info

Product

Resources

About